Compare ADMA Biologics Inc (ADMA) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Ulta Beauty Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Ulta Beauty Inc trades at $456.79 (market cap $19.51B). The key difference: Ulta Beauty Inc is far larger — about 9.2× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ULTA | |
|---|---|---|
Market Cap | $2.13B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $706.82 |
52-Week Low | $7.60 | $450.75 |
Enterprise Value | $2.20B | $21.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ULTA Beauty trades at $453.78, down 1.64% recently, with a bearish technical signal from moving averages but oversold RSI near 29. The stock shows strong profitability with a 9.36% net margin and 47.45% ROE, though revenue growth slowed to $11.3B in 2025. Recent news highlights partnerships with Bath & Body Works and AI-driven loyalty initiatives to boost engagement.
Analysts remain bullish with a $623.73 consensus target, citing valuation discounts and market share gains. Risks include competitive pressures and margin compression, but the current P/E of 16.96 offers value if execution improves. The stock presents a contrarian opportunity amid negative sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
